Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease
Ivana Trapani(University of Naples Federico II), Alberto Auricchio(Federico II University Hospital)
Cited by 93
Related Papers
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
|Science Translational Medicine|2012|390
Effective delivery of large genes to the retina by dual AAV vectors
|EMBO Molecular Medicine|2013|258
Triple Vectors Expand AAV Transfer Capacity in the Retina
|Molecular Therapy|2017|124